Idiopathic Short Stature (ISS) Growth Study — Clinical Trial, Orange City FL
Evaluating Vosoritide, an investigational therapy designed to support bone growth and improve height outcomes in children with Idiopathic Short Stature.
At a glance
This study is registered on ClinicalTrials.gov, the U.S. National Library of Medicine's public trial registry. You can independently verify its details, sponsor, and status under identifier NCT06382155.
Who may qualify
The screening call takes about 5 minutes. Coordinators will walk you through the full eligibility criteria; the items below are the most common gates.
- Females age 3 to <10 years
- Males age 3 to <11 years
- Height Z-score ≤ −2.25
- Tanner Stage I
- No prior growth therapies
What you receive
Tap any item for details.
How to enroll
The fastest path is to submit the pre-qualification form on this page or call the enrollment line at 386-218-5911. A study coordinator will review your information and call you within one business day to schedule a free screening visit.
You are never obligated to continue. You can stop at any step — before signing consent, during screening, or at any point after enrollment.
About the site
This study is conducted at Optimal Research Sites, an independent clinical trial facility in Orange City, Florida. We've conducted Phase I–IV trials since 1994, with a dedicated 9-bed Phase I inpatient unit, certified sample processing laboratory, and a bilingual study team. Every trial runs under IRB oversight and ICH Good Clinical Practice standards.
Other open studies.
Type 2 Diabetes with Obesity
Evaluating a new investigational therapy for adults with Type 2 Diabetes and obesity — measuring weight loss, metabolic health, and glycemic control.
See study →COPD with Type 2 Inflammation
Testing Depemokimab — an investigational long-acting anti–IL-5 therapy — to reduce exacerbations in adults with moderate-to-severe COPD.
See study →Major Depressive Disorder — Relapse Prevention
Testing Brenipatide alongside standard antidepressant therapy to delay or prevent relapse in adults currently in remission from MDD.
See study →